Immunitybio Inc (IBRX) Stock Price, Quote & News

Company Profile

ImmunityBio, Inc., a commercial stage biotechnology company, develops next-generation therapies that bolster the natural immune systems to defeat cancers and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead b...

Industry: Biotechnology

Sector: Healthcare

Phone: 844 696 5235

Website: immunitybio.com

Address:

3530 John Hopkins Court, San Diego, United States

oceanviewhi Feb. 4 at 1:47 AM

$IBRX • The "Triangle Offense" Integration: The "World Bank" provides the Innate power (NK cells), while Anktiva (the IL-15 superagonist) acts as the "Supercharger" to expand them once they are infused. This is why the Lymphopenia BLA on February 20th is so critical—the BLA is the legal right to use the "Bank" to restore a patient's immune system. With the recent Saudi Food and Drug Authority (SFDA) approval and the Mena expansion, the "World Bank" is becoming a global network. Dr. Pat is positioning this as the "Global BioShield," where any nation can "withdraw" immune competence on demand to fight cancer or the next pandemic. The $6.31 Synthesis: You are valuing it as a company that has "Pre-Made the Immune System." When the February 20th BLA filings for Pancreatic and Lymphopenia hit, the market will realize that $IBRX doesn't just have a pipeline—it has a Vault. Tomorrow's MAHA telecast at 4:00 PM ET is the moment the world finds out that the "Bank" is open for business.

0 · Reply

Bc3345 Feb. 4 at 1:44 AM

$IBRX The premise is that animal life which is over 500,000,000 old has specific cells that fight illness or disease or threats to the whole organism. Like cells to see hear and smell exist. It is not farfetched an idea. The sell side the shorts seem to be getting fearful of trading in more than one day increments and are closing positions overnight.

1 · Reply

oceanviewhi Feb. 4 at 1:44 AM

$IBRX • "Off-the-Shelf" Scalability: Because these cells are allogeneic (off-the-shelf), they are cryopreserved in a "blood bag" format. This means a patient in a rural clinic or a hospital in Saudi Arabia can receive a dose of t-haNK or CAR-NK cells instantly, without the 3-week "vein-to-vein" wait time of competitors. • The "Outpatient" Commercial Moat: This "Bank" allows $IBRX to avoid the ICU. Because the cells are standardized and don't require the "nuclear bomb" of lymphodepletion chemotherapy, they are administered in an outpatient setting. This lowers the cost of delivery by hundreds of thousands of dollars per patient, protecting the high margins.

0 · Reply

oceanviewhi Feb. 4 at 1:42 AM

$IBRX While others are struggling with the "Logistics of One" (CAR-T), Dr. Pat has built the "Logistics of Billions." Here is the breakdown of the World Bank of NK Cells and how it fuels your February 20th BLA thesis: • The GMP-Compliant NK Cell-Line Bank: ImmunityBio owns what is believed to be the world’s only Good Manufacturing Practices (GMP)-compliant NK cell-line bank. This isn't just a freezer; it is a proprietary, proprietary-source repository of NK-92 cells that have been validated and authorized by the FDA under multiple INDs. • Three Trillion Cells Manufactured: As of early 2026, the company has already manufactured over 3 trillion NK cells. It allows for a scale that traditional CAR-T (which requires harvesting a patient's own exhausted cells) can never reach.

0 · Reply

burchrealtync Feb. 4 at 1:38 AM

$IBRX https://www.youtube.com/watch?v=980iFjPDDxU Glad to be here with other investors. Sleep well. Until tomorrow then.

0 · Reply

burchrealtync Feb. 4 at 1:35 AM

$IBRX I hope this brings greater stability and honesty in our financial markets going forward. We need legitimate statistics to protect our stock markets.

0 · Reply

oceanviewhi Feb. 4 at 1:31 AM

$IBRX HIV Acute Infection (Thailand Trial): A Phase 2 trial (NCT04505501) in collaboration with the U.S. Military HIV Research Program. This study is testing if giving Anktiva at the very moment of infection can prevent the virus from ever establishing a "reservoir" in the first place. • Tuberculosis (rBCG): As you noted with the February 20th Papillary BLA window, ImmunityBio is working on a Recombinant BCG (rBCG). While currently focused on bladder cancer, the underlying tech is a vaccine for Tuberculosis. This is critical for global health security, particularly in the Mena and Saudi markets where $IBRX just received accelerated approvals. • HPV (QUILT-3.100): A Phase 1 trial (NCT05976828) targeting HPV-associated tumors (Head & Neck Cancer). While "oncology-adjacent," this is effectively a trial to see if Anktiva can eliminate the HPV virus that causes the cancer.

0 · Reply

h8888l Feb. 4 at 1:30 AM

$IBRX watch and spread the good news!!!

0 · Reply

oceanviewhi Feb. 4 at 1:29 AM

$IBRX Here is the current status of the Infectious Disease trials for $IBRX as of February 3, 2026: • Long COVID (COVID-4.019-LONG): This is the trial Dr. Pat telegraphed during the January updates. It is a Phase 2 study (NCT07123727) designed to "clear" the viral reservoir. The thesis is that Anktiva's IL-15 mechanism restores the T-cell memory that was exhausted by the initial infection. In your terms, it’s a "reboot" of the human immune system. • HIV "Kick and Kill" (ACTG/NIAID): ImmunityBio is partnered with the National Institutes of Health (NIH) on a Phase 1/2 trial. Anktiva (N-803) acts as the "kick" to force the dormant HIV out of the cellular reservoirs, while the body’s natural killer cells (activated by Anktiva) provide the "kill." This is the only platform in the world with the biological "teeth" to attempt a functional cure for HIV.

1 · Reply

KissMyAngus02 Feb. 4 at 1:25 AM

$IBRX. Bozo, selling an approved drug isnt a partnership. It's selling drugs. ...and the cost of the ip is a sunken cost recaptured via sales. Fools

0 · Reply

These 10 Stocks Could Be Short Squeeze Targets: Lucid, Kohl's, Avis and More

CAR KSS LCID CHH HIMS MARA TMDX

Feb 2, 2026, 7:00 AM EST - 1 day ago

ImmunityBio Launches Phase 2 Chemotherapy-Free CAR-NK Cell Therapy Trial with ANKTIVA® (ResQ215B) in Indolent Lymphomas

Jan 23, 2026, 7:00 AM EST - 11 days ago

ImmunityBio Reports Median Overall Survival Not Yet Reached and Lymphopenia Reversed in Recurrent Glioblastoma Patients Receiving ANKTIVA® Plus CAR-NK, Chemo-Free Therapy

Jan 20, 2026, 1:47 PM EST - 14 days ago

FDA Talks Set Path For Expanded Use For ImmunityBio's Anktiva In Bladder Cancer

Jan 20, 2026, 8:46 AM EST - 14 days ago

Top 3 Health Care Stocks You May Want To Dump In January

VERO

Jan 20, 2026, 4:00 AM EST - 14 days ago

ImmunityBio Advances Regulatory Discussions with FDA on Potential Resubmission Path for ANKTIVA® in BCG-Unresponsive Papillary Bladder Cancer

Jan 16, 2026, 3:45 PM EST - 18 days ago

ImmunityBio, Inc. (IBRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 16, 2026, 12:52 PM EST - 18 days ago

ImmunityBio Stock Soars On Cancer Trial Progress, FDA Timeline

Jan 16, 2026, 11:04 AM EST - 18 days ago

ImmunityBio's 700% Revenue Boom Becomes Citadel's Latest I‑Told‑You‑So

Jan 16, 2026, 10:41 AM EST - 18 days ago

Looking For A Short Squeeze? 10 Stocks Ready To Rocket

CAR CHH HIMS KSS LCID MARA PCT

Jan 16, 2026, 7:00 AM EST - 18 days ago

ImmunityBio Announces Durable Complete Response of 15 Months with a Chemotherapy-Free CD19 CAR-NK Cell Therapy in Waldenstrom Lymphoma

Jan 16, 2026, 7:00 AM EST - 18 days ago

ImmunityBio Advances First-Line BCG Naive NMIBC Program with Enrollment Exceeding Expectations and Positive Interim Analysis for ANKTIVA® Plus BCG

Jan 16, 2026, 5:52 AM EST - 18 days ago

This Biotech Stock Is Up 100% This Year. Why It's Soaring Again Today.

Jan 15, 2026, 12:50 PM EST - 19 days ago

ImmunityBio: Why I Am Upgrading To A Buy For 2026

Jan 15, 2026, 12:43 PM EST - 19 days ago

ImmunityBio Clocks 700% Revenue Surge In 2025 From Lead Bladder Cancer Drug

Jan 15, 2026, 8:30 AM EST - 19 days ago

ImmunityBio Reports Continued Execution and Sales Momentum With $113 Million of Preliminary Net Product Revenue—a 700% increase year-over-year

Jan 14, 2026, 8:30 AM EST - 20 days ago

Saudi FDA Grants Accelerated Approval to ImmunityBio's ANKTIVA® In Combination with Checkpoint Inhibitors for Metastatic Non-Small Cell Lung Cancer

Jan 14, 2026, 8:30 AM EST - 20 days ago

Saudi FDA Grants Accelerated Approval to ImmunityBio's ANKTIVA® for Non-Muscle Invasive Bladder Cancer with Carcinoma In-Situ

Jan 13, 2026, 8:30 AM EST - 21 days ago

ImmunityBio Announces Positive Results Demonstrating ANKTIVA® as a Lymphocyte Stimulating Agent in Combination With Checkpoint Inhibitors in Non-Small Cell Lung Cancer

Jan 12, 2026, 8:30 AM EST - 22 days ago

NantWorks and ImmunityBio Announce Inaugural U.S.-Saudi Biotech Alliance Summit to Advance Immunotherapy 2.0 and Global Health Security

Dec 29, 2025, 9:00 AM EST - 5 weeks ago

ImmunityBio Founder Dr. Patrick Soon-Shiong Recognized as One of “100 Most Influential People in Oncology in 2025”

Dec 16, 2025, 9:00 AM EST - 7 weeks ago

ANKTIVA® with BCG Demonstrates 96% Survival from Bladder Cancer at Three Years with Median Survival Not Yet Reached in BCG-Unresponsive High-Grade Papillary-Only Non-Muscle Invasive Bladder Cancer

Dec 12, 2025, 12:00 PM EST - 7 weeks ago

ImmunityBio Moves Closer To EU Approval For Bladder Cancer Therapy

Dec 12, 2025, 6:10 AM EST - 7 weeks ago

ImmunityBio Receives Conditional Marketing Authorization Recommendation from the European Medicines Agency for ANKTIVA® with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ—A First in Europe

Dec 3, 2025, 5:00 AM EST - 2 months ago

A Second Anktiva Approval Could Be The Catalyst ImmunityBio Needs

Nov 19, 2025, 4:56 AM EST - 2 months ago

ImmunityBio: Checking The Boxes Of A True Commercial-Stage Biotech

Nov 13, 2025, 9:00 AM EST - 2 months ago

New Survey Reveals Non-Muscle Invasive Bladder Cancer Patients Seek More Care Conversations

Nov 4, 2025, 10:12 PM EST - 3 months ago

Driven by Strong Demand, ImmunityBio Reports 467% Year-to-Date Unit Growth and $75 Million in Sales Year-to-Date, Up 434% from Q3 2024

Oct 22, 2025, 1:42 PM EDT - 3 months ago

Looking For The Next Beyond Meat? Here Are The Top 10 Most Shorted Stocks

AI APLD ENVX HIMS PLUG RKT RXRX

Oct 3, 2025, 1:24 PM EDT - 4 months ago

ImmunityBio: A Small Bet Is Warranted

Sep 11, 2025, 12:26 PM EDT - 5 months ago

ImmunityBio: Still Too Early To Judge Anktiva, Although Clock Is Ticking

Sep 8, 2025, 8:30 AM EDT - 5 months ago

ImmunityBio's ANKTIVA® Reverses Lymphopenia and Extends Overall Survival in Patients With Advanced Non-Small Cell Lung Cancer Resistant to Checkpoint Therapy

Aug 26, 2025, 8:30 AM EDT - 5 months ago

Initial Data Shows 100% Disease Control in 5 Out of 5 Patients With Recurrent Glioblastoma With Two Patients in Near Complete Response Treated With ImmunityBio's ANKTIVA®, NK Cell Therapy Plus Optune Gio® Device

Aug 19, 2025, 8:30 AM EDT - 6 months ago

ImmunityBio Announces Phase 2 Study of ANKTIVA® in Patients with Long COVID

Aug 13, 2025, 8:30 AM EDT - 6 months ago

ImmunityBio Reports Complete Responses in Non-Hodgkin Waldenstrom Lymphoma Patients with Chemotherapy-Free, First-In-Class CD19 CAR-NK Immunotherapy

Aug 11, 2025, 8:30 AM EDT - 6 months ago

ImmunityBio Announces Houston's Michael E. DeBakey VA Medical Center Is Among the First VA Hospitals to Administer ANKTIVA® to Bladder Cancer Patients

Aug 5, 2025, 7:00 AM EDT - 6 months ago

ImmunityBio Reports Q2 Earnings Release Reflecting 60% Increase in Revenue in Q2 2025, With Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-code

Jul 25, 2025, 6:03 AM EDT - 6 months ago

ImmunityBio, Inc. Announces Execution of $80 Million Equity Financing from Multiple Institutional Investors

Jul 25, 2025, 6:00 AM EDT - 6 months ago

ImmunityBio Reports 60% Increase in Revenue in Q2 2025, with Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-Code with Regulatory Updates

Jul 21, 2025, 10:45 AM EDT - 7 months ago

ImmunityBio: Still Flashing Signs Of Life After Another Anktiva Approval

Jul 7, 2025, 9:43 PM EDT - 7 months ago

UK MHRA Approves ImmunityBio's ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

Jun 12, 2025, 9:09 AM EDT - 8 months ago

ImmunityBio: Lymphopenia Opportunity Could Provoke Short Squeeze

Jun 3, 2025, 8:45 AM EDT - 8 months ago

ASCO Report of Pioneering Treatment of Lymphopenia with Significant Overall Survival Benefit in Advanced Pancreatic Cancer

Jun 2, 2025, 9:00 AM EDT - 8 months ago

ImmunityBio Receives FDA Expanded Access Authorization for Landmark Treatment of Lymphopenia With ANKTIVA®, the Cancer BioShield™ Platform, in Patients With Solid Tumors

May 27, 2025, 8:00 AM EDT - 9 months ago

ImmunityBio, Saudi Arabia's Ministry of Investment, KFSHRC, and KAIMRC Sign Strategic Memorandum of Understanding to Launch Cancer BioShield™ Platform in the Middle East

May 12, 2025, 6:30 AM EDT - 9 months ago

ImmunityBio Reports Doubled Net Revenue and 150% Unit Growth in Q1 2025, With Continued Strong Sales Momentum in First Quarter since J-code

May 5, 2025, 5:05 PM EDT - 9 months ago

ImmunityBio: Getting Whiplash After FDA's Refusal To File For Anktiva's sBLA

May 5, 2025, 9:21 AM EDT - 9 months ago

ImmunityBio Slapped With FDA Refusal To File Letter For Expanded Use Of Its Bladder Cancer Drug

May 5, 2025, 6:30 AM EDT - 9 months ago

ImmunityBio Requests an Urgent Meeting With FDA to Address the Change in the Agency's Unambiguous Guidance on Jan 2025 to Submit a sBLA for NMIBC BCG Unresponsive Papillary Disease, Following an Inconsistent Refusal to File Letter on May 2, 2025

oceanviewhi Feb. 4 at 1:47 AM

0 · Reply

Bc3345 Feb. 4 at 1:44 AM

1 · Reply

oceanviewhi Feb. 4 at 1:44 AM

0 · Reply

oceanviewhi Feb. 4 at 1:42 AM

0 · Reply

burchrealtync Feb. 4 at 1:38 AM

$IBRX https://www.youtube.com/watch?v=980iFjPDDxU Glad to be here with other investors. Sleep well. Until tomorrow then.

0 · Reply

burchrealtync Feb. 4 at 1:35 AM

$IBRX I hope this brings greater stability and honesty in our financial markets going forward. We need legitimate statistics to protect our stock markets.

0 · Reply

oceanviewhi Feb. 4 at 1:31 AM

0 · Reply

h8888l Feb. 4 at 1:30 AM

$IBRX watch and spread the good news!!!

0 · Reply

oceanviewhi Feb. 4 at 1:29 AM

1 · Reply

KissMyAngus02 Feb. 4 at 1:25 AM

$IBRX. Bozo, selling an approved drug isnt a partnership. It's selling drugs. ...and the cost of the ip is a sunken cost recaptured via sales. Fools

0 · Reply

MrStockxy Feb. 4 at 1:25 AM

$IBRX it will take us exactly one year 02/2027 to get to 40$

0 · Reply

MrStockxy Feb. 4 at 1:23 AM

$IBRX this is where we are. There will be ups and downs - but once we are up we are not going down anymore.

1 · Reply

Texas12 Feb. 4 at 1:21 AM

$IBRX Might have to raise my GTC orders. Should have filled today on the selloff but this stayed strong 💪🏽

0 · Reply

Cancercrusader Feb. 4 at 1:19 AM

$IBRX https://www.instagram.com/reel/DURW7n9jtoM/?igsh=YjZ3cXhsNzZ6Nmdk

0 · Reply

oceanviewhi Feb. 4 at 1:16 AM

$IBRX Bio Frog , I can’t find the info I thought I saw on the Lymphopenia and Pancreatic BLA submissions. February 20th is not a "hard” date , like Papillary is . But I think they will be submitted in February, together.

0 · Reply

Biofrog Feb. 4 at 1:15 AM

$IBRX All this stuff lined up in February is amazing. Sometimes I think that I would give up the next 25 days of my life just to know how this goes. It is just so big.

0 · Reply

KissMyAngus02 Feb. 4 at 1:09 AM

$IBRX honestly, what is wrong w all your fucking heads?? SA just threw ibrx a bone. Now you think theyre also going to invest in the company? Name another country that approved a drug and invested in a partnership. You fucking idiots keep creating false expectations. Fuck off w your non stop pumping. Never ends.

1 · Reply